Literature DB >> 17629359

[Systemic corticosteroid treatment and risk of infectious diseases].

H Dussauze1, I Bourgault, L-M Doleris, J Prinseau, A Baglin, T Hanslik.   

Abstract

PURPOSE: It was shown that corticosteroids alter the inflammatory and immune responses. Many publications report on serious infections occurring in patients receiving corticosteroids or presenting with Cushing's syndrome. This information is synthesized in this article. CURRENT KNOWLEDGE AND KEY POINTS: The demonstration of the infectious risk associated with corticosteroids relies on observational data and on biological plausibility. However, this risk remains difficult to quantify, because of many confusing factors such as the patients' associated conditions and immunosuppressive treatments, and the highly variable dose and duration of the corticosteroid treatment. Taking into account the published data, the screening for a chronic infection seems licit among patients receiving a systemic corticosteroid treatment, in particular for those who will receive more than 10 mg of prednisone per day. FUTURE PROSPECTS: Although no clinical trials of prevention of infections in corticosteroid treated patients has been published, a strategy aiming at minimizing the infectious risk of corticosteroid treated patients is proposed, based on the analysis of the literature presented in this article.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17629359     DOI: 10.1016/j.revmed.2007.05.030

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  2 in total

1.  Impact of anti-inflammatory drug consumption in peritonsillar abscesses: a retrospective cohort study.

Authors:  Thomas Feasson; Mathilde Debeaupte; Clément Bidet; Florence Ader; François Disant; Tristan Ferry; Christian Chidiac; Florent Valour
Journal:  BMC Infect Dis       Date:  2016-08-20       Impact factor: 3.090

Review 2.  Endocrine risk factors for COVID-19: Endogenous and exogenous glucocorticoid excess.

Authors:  Frederick Vogel; Martin Reincke
Journal:  Rev Endocr Metab Disord       Date:  2021-07-09       Impact factor: 6.514

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.